New Sigma-1 receptor-BiP biosensor

New Sigma-1 receptor-BiP biosensor

Scientists from the Pathology and Experimental Therapeutics Dept., Facultat de Medicina i Ciències de la Salut of the Universitat de Barcelona, and scientists from WeLab Barcelona have recently published the paper: “Development of a Novel σ1 Receptor Biosensor Based on Its Heterodimerization with Binding Immunoglobulin Protein in Living Cells” in a ACS Chemical Neuroscience special issue. The paper describes the development of a new Sigma-1 receptor-BiP biosensor as a simple and effective tool for exploring Sigma-1 receptor pharmacology in an easy cellular setting, which it has been something hard to achieve in the sigma field for many years. The biosensor is suitable for high-throughput applications and it may become a relevant tool in the sigma receptor field. Congratulations to Xavier Morato Arus, PhD, Victor Fernández Dueñas, Pilar Pérez Villamor, Marta Valle León, Jose Miguel Vela, Manuel Merlos, Javier Burgueño Hurtado and Francisco Ciruela.

Link to the publication: https://lnkd.in/ezXf_asE

#simga-1; #receptor; #oligomerization; #HTS; #pharmacology #pharmaceutical

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS